UBS Group’s Spark Therapeutics, Inc. Common Stock ONCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q4 | – | Sell |
-130,654
| Closed | -$12.7M | – | 8698 |
|
|
2019
Q3 | $12.7M | Buy |
130,654
+96,679
| +285% | +$9.68M | ﹤0.01% | 1580 |
|
|
2019
Q2 | $3.48M | Sell |
33,975
-62,082
| -65% | -$6.7M | ﹤0.01% | 2633 |
|
|
2019
Q1 | $10.9M | Buy |
96,057
+87,903
| +1,078% | +$6.46M | ﹤0.01% | 1612 |
|
|
2018
Q4 | $319K | Sell |
8,154
-1,165
| -13% | -$50.5K | ﹤0.01% | 4587 |
|
|
2018
Q3 | $508K | Sell |
9,319
-3,511
| -27% | -$240K | ﹤0.01% | 4387 |
|
|
2018
Q2 | $1.06M | Sell |
12,830
-99,594
| -89% | -$7.69M | ﹤0.01% | 3735 |
|
|
2018
Q1 | $7.49M | Buy |
112,424
+58,069
| +107% | +$3.35M | ﹤0.01% | 1940 |
|
|
2017
Q4 | $2.79M | Sell |
54,355
-23,046
| -30% | -$1.66M | ﹤0.01% | 2891 |
|
|
2017
Q3 | $6.9M | Buy |
77,401
+58,545
| +310% | +$4.45M | ﹤0.01% | 1902 |
|
|
2017
Q2 | $1.13M | Buy |
18,856
+14,832
| +369% | +$829K | ﹤0.01% | 3510 |
|
|
2017
Q1 | $215K | Sell |
4,024
-39,954
| -91% | -$2.37M | ﹤0.01% | 4613 |
|
|
2016
Q4 | $2.19M | Buy |
43,978
+34,317
| +355% | +$1.84M | ﹤0.01% | 2844 |
|
|
2016
Q3 | $580K | Buy |
9,661
+2,237
| +30% | +$129K | ﹤0.01% | 3818 |
|
|
2016
Q2 | $380K | Sell |
7,424
-11,384
| -61% | -$486K | ﹤0.01% | 4104 |
|
|
2016
Q1 | $555K | Sell |
18,808
-17,488
| -48% | -$552K | ﹤0.01% | 3700 |
|
|
2015
Q4 | $1.65M | Buy |
36,296
+30,403
| +516% | +$1.59M | ﹤0.01% | 2987 |
|
|
2015
Q3 | $246K | Buy |
5,893
+5,693
| +2,847% | +$297K | ﹤0.01% | 4469 |
|
|
2015
Q2 | $12K | Sell |
200
-851
| -81% | -$56.3K | ﹤0.01% | 7351 |
|
|
2015
Q1 | $82K | Buy |
+1,051
| New | +$60.5K | ﹤0.01% | 5588 |
|
UBS Group's ONCE Position: Q4 2019 in Review
UBS Group sold out of Spark Therapeutics, Inc. Common Stock (ONCE) in Q4 2019, closing a stake of 130,654 shares — an estimated $12.7M sold.
UBS Group first reported a position in ONCE in Q1 2015 and held it in 19 quarters. The position peaked at $12.7M in Q3 2019. 0 funds tracked by Wall St. Rank hold ONCE as of Q4 2019.
- UBS Group reported no remaining Spark Therapeutics, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
- UBS Group sold 130,654 Spark Therapeutics, Inc. Common Stock shares in Q4 2019, an estimated $12.7M.
- UBS Group first reported a position in Spark Therapeutics, Inc. Common Stock in Q1 2015 and held it in 19 quarters.
- UBS Group's Spark Therapeutics, Inc. Common Stock position peaked at $12.7M in Q3 2019.
- 0 funds tracked by Wall St. Rank held Spark Therapeutics, Inc. Common Stock as of Q4 2019.
Based on UBS Group's 13F filing for Q4 2019, filed 14 Feb 2020.